IGC Pharma, Inc. insider trading

Every open-market purchase and sale by IGC Pharma, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following IGC Pharma, Inc.’s insiders pay?

From January 13, 2012 to September 27, 2024, 5 insiders reported 3 open-market purchases and 14 sales not made under a pre-set plan in IGC Pharma, Inc.

IGC Pharma, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Mukunda Ram	Exec. Chairman & CEO	0	—	—	7	—	March 8, 2021
Prins Richard K	Director	0	—	—	5	—	March 10, 2021
Grimaldi Claudia	Vice President and PFO	0	—	—	2	—	August 31, 2018
Krishna Ranga C	Director	2	—	—	0	—	September 7, 2012
Moran James P	Director	1	—	—	0	—	September 27, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to IGC Pharma, Inc. · Funds · Politicians